Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
In March, the FDA approved DexCom Inc's (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM).
三月份，美國食品和藥物管理局批准了德康醫療公司（納斯達克股票代碼: DXCM）的Stelo葡萄糖生物傳感器系統，作爲第一個非處方（OTC）連續葡萄糖監測器（CGM）。
The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for people 18 and older who do not use insulin.
德康醫療的Stelo葡萄糖生物傳感器系統是一種集成CGM（iCGM），適用於18歲及以上不使用胰島素的人群。
On Monday, DexCom announced Stelo is now available for purchase without a prescription at Stelo.com.
週一，德康醫療宣佈Stelo現在可在Stelo.com上無需處方購買。
Stelo is a small biosensor worn on the back of the upper arm.
Stelo是一個小型生物傳感器，佩戴在上臂背面。
It is specifically designed to provide the 125 million Americans with Type 2 diabetes who are not using insulin and those with prediabetes with personalized glucose insights sent directly to their smartphones.
它專門設計爲向1,2500萬不使用胰島素的美國2型糖尿病患者和有糖尿病前期的人提供個性化葡萄糖洞察，直接發送至他們的智能手機。
These insights reveal how food, exercise, and sleep can affect glucose—all without painful fingersticks.
這些洞察揭示了食物、運動和睡眠如何影響葡萄糖，而無需痛苦的戳指血檢。
Also Read: Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers.
另請閱讀：雅培公司積極推廣新葡萄糖監測器，瞄準健康意識消費者。
Users can buy a one-month supply online for $99 (for a single pack of two sensors (total wear time up to 30 days) or sign up for an ongoing subscription at $89 a month.
用戶可以在網上以99美元購買一個月的供應（兩個傳感器的單獨包裝（總佩戴時間長達30天），或者以89美元/月的價格訂閱連續購買。
In June, the FDA approved two new over-the-counter continuous glucose monitoring (CGM) systems from Abbott Laboratories (NYSE:ABT): Lingo and Libre Rio. These systems are based on Abbott's FreeStyle Libre technology, which is now used by about 6 million people globally.
六月份，美國食品和藥物管理局（FDA）批准了雅培實驗室（紐交所: ABT）推出的兩款新的可購買的連續葡萄糖監測（CGM）系統：Lingo和Libre Rio。這些系統基於雅培的FreeStyle Libre技術，目前全球約有600萬人使用。
Reuters noted that Lingo has been available in Britain since January for $152-$190 (120-150 pounds) per month.
路透社指出，Lingo自今年1月起在英國上市，每月售價爲152-190美元（120-150英鎊）。
Jake Leach, chief operating officer at Dexcom, told CNBC in an interview that Dexcom is working with Amazon to fulfill Stelo deliveries.
Dexcom首席運營官傑克·利奇在接受CNBC採訪時表示，Dexcom正在與亞馬遜合作，完成Stelo的交付。
Dexcom said patients also have the option to use their flexible spending accounts and health savings accounts to pay for Stelo, CNBC noted.
Dexcom表示，患者還可以選擇使用自己的靈活支出帳戶和醫療儲蓄帳戶來支付Stelo，CNBC指出。
Stelo is a small, gray device worn on the upper arm, about the size of a quarter and half an inch thick, with a 15-day lifespan before needing replacement. It wirelessly transmits data to a smartphone app, where users specify whether they have Type 2 diabetes, prediabetes, or neither. This information sets a "Target Range" for maintaining optimal glucose levels.
Stelo是一款佩戴在上臂上的小巧灰色裝置，大約是一個25美分硬幣的大小，厚度約半英寸，使用壽命爲15天，在需要更換前無線傳輸數據到智能手機應用程序，用戶可以指定是否患有2型糖尿病、糖尿病前期或兩者都沒有。這些信息設置了維持血糖水平的「目標範圍」。
Price Action: DXCM stock is up 0.48% at $74.43 at last check Monday.
股票價格表現: 德康醫療股票最近的檢查顯示漲幅爲0.48%，報74.43美元。
- Baker Hughes Says US Oil And Gas Rig Count Declines For Second Week: Report
- baker hughes表示，美國石油和燃料幣鑽井數量連續第二週下降。
Photo: Shutterstock
Photo: shutterstock